How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?

Yvette I. Sheline; Kenneth E. Freedland; Robert M. Carney

doi:10.1016/S0002-9343(96)00374-9

How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?

Yvette I. Sheline, Kenneth E. Freedland, Robert M. Carney

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Depression occurs frequently in patients with coronary heart disease (CHD), and confers significant risk for additional morbidity and mortality. The cardiac effects of the tricyclic antidepressants (TCAs) have been well characterized. In contrast, the cardiac effects of the selective serotonin reuptake inhibitors (SSRIs) have been less thoroughly investigated. The Medline database from 1986 to 1996 was searched for all reports of cardiac effects of SSRIs, and this literature is summarized. In addition, potential drug interactions, reports of side effects, and efficacy studies in the elderly are reviewed. Finally, recommendations are made considering the risk/benefit ratio.

Original language	English
Pages (from-to)	54-59
Number of pages	6
Journal	American Journal of Medicine
Volume	102
Issue number	1
DOIs	https://doi.org/10.1016/S0002-9343(96)00374-9
State	Published - Jan 1997

Access to Document

10.1016/S0002-9343(96)00374-9

Cite this

@article{40556e2d22c9419c8321d42b094b044d,

title = "How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?",

abstract = "Depression occurs frequently in patients with coronary heart disease (CHD), and confers significant risk for additional morbidity and mortality. The cardiac effects of the tricyclic antidepressants (TCAs) have been well characterized. In contrast, the cardiac effects of the selective serotonin reuptake inhibitors (SSRIs) have been less thoroughly investigated. The Medline database from 1986 to 1996 was searched for all reports of cardiac effects of SSRIs, and this literature is summarized. In addition, potential drug interactions, reports of side effects, and efficacy studies in the elderly are reviewed. Finally, recommendations are made considering the risk/benefit ratio.",

author = "Sheline, {Yvette I.} and Freedland, {Kenneth E.} and Carney, {Robert M.}",

note = "Funding Information: Preparation of this manuscript was supported in part by Grant #1K07 MHO1370-01A1, NIMH, Y. Sheline, MD, PI; #2R01HL4247-04 from the National Heart, Blood and Lung Institute, NIH, R. Carney, PhD, PI; and #5R01 MH51419-02, NIMH, K. Freedland, PhD, PI.",

year = "1997",

month = jan,

doi = "10.1016/S0002-9343(96)00374-9",

language = "English",

volume = "102",

pages = "54--59",

journal = "American Journal of Medicine",